Pylopass MONO for H. pylori

Sale price33,00 €(1.434,78 € / 1kg)

Tax included. Shipping calculated at checkout


  • Pylopass™ for Helicobacter pylori infection

Pylopass™ for Helicobacter pylori infection.

Our Pylopass MONO capsules contain the patented raw material Pylopass™ - an inactivated Lactobacillus reuteri lactic acid bacterium strain. This bacterial strain is used for the dietary management of Helicobacter pylori infections. Without side effects!

  • Pylopass™ for Helicobacter pylori infection

Pylopass™ for Helicobacter pylori infection.

Our Pylopass MONO capsules contain the patented raw material Pylopass™ - an inactivated Lactobacillus reuteri lactic acid bacterium strain. This bacterial strain is used for the dietary management of Helicobacter pylori infections. Without side effects!

  • gluten free

  • lactose-free

  • vegan

  • GMO-free

  • without undesirable additives

  • sugar free

Blaue check Ikone

Branded raw material Pylopass™: A natural, inactivated Lactobacillus reuteri bacterium with the patented strain DSM17648 with 200 mg per capsule.

Blaue check Ikone

Thanks to its special properties, Pylopass™ can bind to Helicobacter pylori in the stomach and excrete it via the faeces.

Blaue check Ikone

Pylopass™ does not affect the natural intestinal flora.

Blaue check Ikone

Pylopass™ has no side effects.

Braune Kapseln in einem weißen Behälter, daneben eine Pflanze

Pylopass™: Natural support for stomach problems caused by H. pylori

Helicobacter pylori infection is now the most common bacterial infectious disease worldwide after tooth decay, affecting approximately half of the world's population. One in two or three Germans suffers from stomach problems caused by Helicobacter pylori. The cause and diagnosis of H. pylori are often only discovered after thorough examinations, and thus this disease often remains undetected for a long time.In some cases, no or no significant symptoms are observed; in others, the infection leads to a serious illness. Presumably, certain conditions in the stomach cause the bacteria to multiply excessively and then cause problems. For example, a temporarily elevated pH level in the stomach (too little acid) could be a reason for excessive Helicobacter proliferation in some people. A healthy stomach acid level keeps Helicobacter pylori in check.

Persistent stomach pain, pressure in the upper abdomen, pain when fasting, constant bloating, heartburn, belching, vomiting, or even recurring nausea, loss of appetite, anemia, and vitamin B12 deficiency can be symptoms of a Helicobacter pylori infection. The long-term consequences often include inflammation of the stomach lining (gastritis), stomach and duodenal cancer, and much more.

Pylopass™ is used for the dietary management of Helicobacter pylori infections. This product contains the natural, but inactivated, lactic acid bacterium Lactobacillus reuteri DSM17648. Through its inactivation, this special bacterial strain gains the ability to bind multiple Helicobacters within seconds.without affecting the natural intestinal bacteria. The unique Pylopass™ lactic acidbound Helicobacter bacteria are excreted in the stool.

Several studies demonstrate the ability of Pylopass™ to remove H. pylori bacteria from the body and show that the quality of life of users improved significantly after only about 2 weeks.

What's special about Pylopass™

  • resistant to stomach acid
  • free of side effects
  • does not change the body's intestinal flora
  • heat-resistant
  • allergen-free
  • suitable for children

Studies on Pylopass™

  1. Buckley et al. (2018) The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study
  2. Kornienko et al. (2020) Gastric opportunities in HP eradication in children
  3. Uspensky et al. (2016) Evolution in eradication therapy of HP -associated diseases: beyond the standards?
  4. Paralova et al. (2015) An innovative approach in the treatment of H. pylori infection in children.
  5. Bordin et al. (2015) The efficacy and safety of probiotic bacteria Lactobacillus reuteri DSMZ17648 in patients infected with Helicobacter pylori, who haven't absolute indications for eradication therapy: results of the study
  6. Wood et al. (2014): Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: a pilot study
  7. Mehling and Busjahn (2013) Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans
  8. Parth K (2021) Efficacy L reuteri triple therapy eradication.